CN101559050A - Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system - Google Patents
Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system Download PDFInfo
- Publication number
- CN101559050A CN101559050A CNA2008101721952A CN200810172195A CN101559050A CN 101559050 A CN101559050 A CN 101559050A CN A2008101721952 A CNA2008101721952 A CN A2008101721952A CN 200810172195 A CN200810172195 A CN 200810172195A CN 101559050 A CN101559050 A CN 101559050A
- Authority
- CN
- China
- Prior art keywords
- butin
- melanocyte
- immune system
- influence
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses use of butin and derivatives thereof for preparing drugs having inhibitive effect on an immune system. The use is characterized by preparing drugs having inhibitive effect on an immune system with the butin and the derivatives thereof as active ingredients and a pharmaceutically acceptable carrier.
Description
Invention field
The present invention relates to the new purposes of a kind of chemical compound and derivant thereof, specifically, is butin and derivant thereof the purposes at the medicine of preparation treatment metabolism of pigment disease such as vitiligo and poliosis.
Background technology
Vitiligo is a common a kind of limitation hypopigmentation dermatoses, and sickness rate is 0.5-2.0%, because pathogenesis and pathogeny are not clear and definite as yet at present, still is in the situation of easily examining refractory in the world so far.This disease is classified as one of difficult and complicated illness by world medical circle.Present leukodermic drug treatment has psoralen combined U VA treatment, 17-hydroxy-11-dehydrocorticosterone therapy, khellin's combined U VA therapy, metallic element to cooperate PUVA therapy, phenylalanine to cooperate UVA therapy and herbal treatment.Caulis Vernoniae andersonii is the achene of feverfew Caulis Vernoniae andersonii Vernoniaanthelmintica Willd.Extract during fruit maturation in the autumn in summer; Or extract ripe Fruit branch respectively, and lay fruit, be stored in shady and cool dry place.Originate in India, Pakistan, the existing cultivation history that is about 400 years in Chinese Xinjiang.Mainly be distributed in the Xinjiang Aksu Prefecture.Be that the Xinjiang uighur folk is treated leukodermic medicine, personnel are made into hospital preparation in the Xinjiang study of pharmacy seventies, are applied to the clinical treatment vitiligo, and cure rate is 7-20%, and effective percentage is greater than 90%, and do not see toxic and side effects.But so far the effective ingredient in the Caulis Vernoniae andersonii be it be unclear that.For this reason, the inventor has carried out further screening and separating work, has found that the chemical compound of other metabolism of pigment diseases such as Caulis Vernoniae andersonii treatment vitiligo and poliosis is a butin, thereby has finished the present invention.
Goal of the invention
The purpose of this invention is to provide butin and derivant thereof purposes at the medicine of preparation treatment metabolism of pigment disease such as vitiligo and poliosis.
Summary of the invention
Butin of the present invention is 3 "-4 '-7-trihydroxy flavanone, structural formula is:
The butin derivant is included in 5,6,7,8, the one group of chemical compound that 3 ', 4 ', 5 ', 6 ' quilt-OH replaces and the corresponding glucoside compound of generation; Or quilt-OR or-one group of chemical compound that R replaces, wherein R is C
1-C
8Alkyl.
It can extract acquisition from plant Caulis Vernoniae andersonii seed or other plant, also can obtain by chemosynthesis.Obtain if from the Caulis Vernoniae andersonii seed, extract, one of extracting method is: use the methanol reflux, obtain methanol extract liquid, reclaim under reduced pressure, concentrate, obtain concentrated solution,, get ethyl acetate layer with ethyl acetate and water dispenser, supernatant is passed through silica gel column chromatography, use the chloroform-methanol gradient elution, obtain eluent, again at silica gel column chromatography petroleum ether-acetone (4: 1-1: 1) eluting, with eluent, reuse polydextran gel LH20 50-80% methanol-eluted fractions obtains eluent, reuse octadecyl silane chromatography, use the 50-100% methanol-eluted fractions, obtain eluent, (10-25: 1) eluting obtains the recycle silicon plastic column chromatography with chloroform-methanol.Turn out to be butin through chromatography.
We carry out pharmacological evaluation and confirm, butin can make melanocyte propagation, the activity of tryrosinase improves, melanin content increases, can improve the melanin synthetic gene (tyrosinase cdna. tryrosinase related gene-1, tryrosinase related gene-2) expression, make melanosome type generation significant change, more trend towards the generation of pigment granule.Therefore, butin can be treated the metabolism of pigment disease.The immunity of butin pair cell, humoral immunization are inhibited.By to serum antibody, complement and T lymphocytic emiocytosis IL-2 activity analysis, further show that at molecular level butin is inhibited to immune system.Butin is to K-1735 SKMel-19, SKMel-23, and Mel-2A, MeWo, Bro. has shown inhibitory action.
Brief description
Fig. 1-----butin and derivant thereof are in external influence to melanin content.
Fig. 2-----butin external to melanocyte in the influence of tyrosinase activity.
Fig. 3-----butin is in external influence to melanocyte propagation.
Fig. 4-----butin influences the melanin synthetic gene expression external.
Fig. 5-----butin external to melanocyte in the influence of melanosome.
Fig. 6-----butin is in the influence to brown guinea pig skin melanocyte.
Fig. 7-----butin is in external influence to the mice spleen lymphocytes proliferation reaction.
Fig. 8-----butin is secreted the active influence of IL-12 external to mouse boosting cell.
Specific embodiment
The external pharmacodynamic study of experimental example 1 butin
Impaired because of the pigment cell and the function thereof in patients with vitiligo skin lesion district, we have studied the influence of butin to the human body melanocyte of In vitro culture.
1.1. experimental program
1.1.1 screening model: normal person's melanocyte;
1.1.2. source: the unnecessary foreskin of child's Wrapping annulus cuts operation, do not have and infect.
1.1.3. condition of culture: obtain melanocyte after getting the trypsinization of normal children foreskin, in the DMEM culture medium, add bFGF, CT, TPA, FCS, two various factors such as anti-, 5%CO
2, to cultivate after 7 days under 37 ℃ of conditions and go down to posterity, passage cell is cultivated medicine and the contrast that adds variable concentrations after 48 hours under these conditions, measures the correlation analysis index.
1.1.4. assay method: cell increment mtt assay; Tyrosinase activity is measured and is used the DOPA staining; Melanin content alkali digestion method; The melanin synthetic gene (tyrosinase cdna. tryrosinase related gene-1, tryrosinase related gene-2) expression Northern Blotting; The electronic microscope photos scanning electron microscope.
1.2. result
1.2.1. butin and derivant thereof external to melanocyte in melanic influence
Butin and derivant thereof external to melanocyte in the content of synthesis of melanin the raising effect is arranged, see Fig. 1.Wherein chemical compound is:
Butin (Butin):
The butin derivative I:
Puerarta chalcone (Butein)
Butin derivative I I:
5,6,7,4 '-kaempferol
1.2.2. butin external to melanocyte in the influence of tyrosinase activity
Butin is seen Fig. 2 in the external activity that improves tryrosinase in the melanocyte.
1.2.3. butin external to the value-added influence of melanocyte
Butin can promote melanocyte propagation, sees Fig. 3.
1.2.4. butin is in external influence to the melanin synthetic gene expression
To its mechanism inquire into draw butin can improve the melanin synthetic gene (tyrosinase cdna. tryrosinase related gene-1, tryrosinase related gene-2) expression, see Fig. 4.
1.2.5. butin external to melanocyte in the influence of melanosome
Can see melanosome type generation significant change from electronic microscope photos, more trend towards the generation of pigment granule.See Fig. 5.
Pharmacodynamic study in the body of experimental example 2. butins
By gastric infusion observe butin to melanocyte in the brown Cavia porcellus body in the influence of the contained ratio of basal layer.
2.1. experimental program
Laboratory animal: the brown Cavia porcellus of Britain's undercoat, the Xinjiang Experimental Animal Center provides.
Be provided with by the reagent thing:
Butin:
High concentration group: 8.74mg/kg (calculating) by 1/25 of maximum tolerated dose
Middle concentration group: 4.37mg/kg (calculating) by 1/50 of maximum tolerated dose
Low concentration group: 2.19mg/kg (calculating) by 1/100 of maximum tolerated dose
Positive controls: 8-MOP (8 methoxypsoralens, Chinese pharmaceutical biological product is identified institute) negative control group: 2.5% hydroquinone blank group; Normal saline
2.2. the foundation of animal model
Elder generation external hydroquinone and Fructus Psoraleae (8-MOP) are observed the influence to coloured guinea pig skin basal layer melanocyte of hydroquinone, 8-MOP: behind the external hydroquinone, coloured guinea pig skin basal layer is thickened, melanin be generated reduce this result to conform to relevant document; After using 8-MOP, coloured guinea pig skin basal layer melanocyte is increased.Determine the model establishment.
2.3. result
Butin can improve the ratio of coloured guinea pig skin basal layer melanocyte.Coloured guinea pig skin basal layer melanocyte had significance to change (P<0.05) before and after the butin of high, medium and low dosage can make medication; There was no significant difference between the butin group of high, medium and low dosage (P>0.05), but numerically change.Wherein middle dosage group is bigger to the influence of coloured guinea pig skin basal layer melanocyte.See Fig. 6.
Experimental example 3. butins are to the influence of mouse immune system
3.1. experimental program
3.1.1. experimental model: cultivating Kunming is the newborn mice splenocyte.
3.1.2. animal origin: the Xinjiang Experimental Animal Center provides.
3.1.3. condition of culture: getting Kunming is to obtain splenocyte after the trypsinization of newborn mice spleen,
In the RPMI1640 culture medium, add FCS, two various factors such as anti-, 5%CO
2, cultivate down under 37 ℃ of conditions and cultivate medicine and the contrast that adds variable concentrations after 48 hours, measure the correlation analysis index.
3.2. result
Support that leukodermic morbidity with immune system relevant because etiological study at present more, find to have in the patients with vitiligo body specific antibody to exist.Carrying out butin shows the result of study of mouse immune systematic influence: the immunity of butin pair cell, humoral immunization are inhibited.By to splenocyte and splenocyte secretion IL-2 activity analysis, further show that at molecular level butin is inhibited to immune system, see Fig. 7,8.
Experimental example 4. butins are in external influence to melanoma cell
Because butin can make melanocyte propagation, we have investigated it in external influence to melanoma cell.
4.1. screening model: K-1735 SKMel-19, SKMel-23, Mel-2A, MeWo, Bro;
4.2. source: Berlin, Germany Free University Benjamin Franklin medical research center.
4.3. condition of culture: in the DMEM culture medium, add FCS, two various factors such as anti-, 5%CO
2, cultivate medicine and the contrast that adds variable concentrations after 24 hours under 37 ℃ of conditions, measure the correlation analysis index.
4.4. assay method: cell increment mtt assay
4.5. result
Butin can be to K-1735 SKMel-19, SKMel-23, and Mel-2A, MeWo, Bro have shown inhibitory action in various degree.
Claims (1)
1. butin and derivant thereof are in the purposes of preparation inhibition immune system drugs with function, and the structural formula of wherein said butin and derivant thereof is:
The butin derivant is included in 5,6,7,8, the one group of chemical compound that 3 ', 4 ', 5 ', 6 ' quilt-OH replaces and the corresponding glucoside compound of generation; Or quilt-OR or-one group of chemical compound that R replaces, wherein R is C
1-C
8Alkyl.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008101721952A CN101559050A (en) | 2004-11-23 | 2004-11-23 | Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008101721952A CN101559050A (en) | 2004-11-23 | 2004-11-23 | Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410091322 Division CN1778294B (en) | 2004-11-23 | 2004-11-23 | Butin and its derivative and its use in preparation of pigmental metabolic disease medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101559050A true CN101559050A (en) | 2009-10-21 |
Family
ID=41218142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008101721952A Pending CN101559050A (en) | 2004-11-23 | 2004-11-23 | Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101559050A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028680A (en) * | 2010-11-24 | 2011-04-27 | 广东省农业科学院兽医研究所 | Application of fisetin for resisting against Eimeria tenella |
CN102526153A (en) * | 2012-02-27 | 2012-07-04 | 新疆维吾尔自治区维吾尔医药研究所 | Vernonia anthelmintica flavone components, preparation method and application thereof |
CN102627623A (en) * | 2012-03-20 | 2012-08-08 | 中国科学院新疆理化技术研究所 | Method for preparing butin from Vernonia anthelmintica fruits |
-
2004
- 2004-11-23 CN CNA2008101721952A patent/CN101559050A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028680A (en) * | 2010-11-24 | 2011-04-27 | 广东省农业科学院兽医研究所 | Application of fisetin for resisting against Eimeria tenella |
CN102028680B (en) * | 2010-11-24 | 2012-05-09 | 广东省农业科学院兽医研究所 | Application of fisetin in preparing medicine for resisting against Eimeria tenella |
CN102526153A (en) * | 2012-02-27 | 2012-07-04 | 新疆维吾尔自治区维吾尔医药研究所 | Vernonia anthelmintica flavone components, preparation method and application thereof |
CN102627623A (en) * | 2012-03-20 | 2012-08-08 | 中国科学院新疆理化技术研究所 | Method for preparing butin from Vernonia anthelmintica fruits |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102219821A (en) | Cardiac glycoside compounds and antitumor application thereof | |
CN1931228B (en) | Lysimachia herb total flavone extract and its preparation process | |
Zheng et al. | Total flavonoids of Daphne genkwa root significantly inhibit the growth and metastasis of Lewis lung carcinoma in C57BL6 mice | |
CN101810812B (en) | Use of rhizoma galangae effect part for preparing medicament for treating leucoderma | |
CN102091111B (en) | Saussurea cataplasm and production method thereof | |
CN103599144B (en) | The preparation method of jatamans valeriana rhizome epoxy iridoid ester active component | |
CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
CN102552243A (en) | Application of myricanol and/or myricanone in preparing antitumor drugs | |
CN102755343A (en) | Application of daucosterol in preparing medicines for promoting proliferation of neural stem cells | |
CN1778294B (en) | Butin and its derivative and its use in preparation of pigmental metabolic disease medicine | |
CN102030800B (en) | Abies holophylla triterpenoid compound, extraction separation thereof and application thereof | |
CN101559050A (en) | Use of butin and derivatives thereof for preparing drugs having inhibitive effect on immune system | |
CN101396373B (en) | Cinobufacini extract and preparation method thereof | |
CN101559051A (en) | Use of butin and derivatives thereof for preparing drugs having inhibitive effect on melanoma | |
CN102362877B (en) | Application of Pouzolzia extract | |
CN101565443B (en) | New fir triterpene lactone compound, preparation method and application thereof | |
CN1778324A (en) | Effective part of nightshadeleaf ironweed for antiscolic medicines and its preparation and use | |
CN105079011A (en) | Preparation and application of anti-tumor medicament | |
CN102626407A (en) | Application of isodaphnetin compound in preparation of antidiabetic medicines | |
CN101948473A (en) | New NEO-clerodane diterpenoid compound and application thereof | |
CN110437198B (en) | Sesquiterpene compound and application thereof | |
CN101062045B (en) | Use of triterpene saponin compounds in preparing tumor medicine | |
CN108997473A (en) | A kind of non-sea cucumber alkane type selenka and the preparation method and application thereof | |
CN100450490C (en) | Use of caudatin-3-O-beta-D-cymaroside as medicament for treating tumour | |
CN101028311B (en) | Use of selaginella tamariscina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091021 |